Clinical Scorecard: A Clinical Perspective on the Pharmacological Algorithm for Obesity Management Based on EASO Grading

At a Glance

Key Highlights

• Obesity is classified into fat mass disease (mechanical complications) and sick fat disease (metabolic/cardiovascular complications).
• Next-generation obesity management medications (OMMs) like GLP-1 and dual GIP/GLP-1 agonists achieve 15%-22% weight loss and improve ORCs.
• The EASO grade-based pharmacological algorithm integrates evidence strength and complication-based staging for personalized treatment.

Guideline-Based Recommendations

Diagnosis

• Classify obesity by adipose-based disease subtype and assess obesity-related complications (ORCs) beyond BMI.
• Use the new EASO staging system incorporating ORC presence and severity.

Management

• Apply the EASO grade-based pharmacological algorithm to guide OMM selection based on evidence levels and clinical priorities.
• Combine pharmacotherapy with lifestyle interventions for sustainable long-term outcomes.
• Consider long-term use of OMMs given favorable safety profiles and efficacy comparable to bariatric surgery.

Monitoring & Follow-up

• Monitor weight loss durability and remission of ORCs over time, recognizing current limited long-term data.
• Assess patient response across BMI categories and ORC status to personalize therapy.
• Be vigilant for access and adherence issues that may affect treatment continuity.

Risks

• Recognize limited data on long-term safety and efficacy in under-represented populations (BMI ≥40 kg/m², adolescents, overweight individuals).
• Address disparities in regulatory approvals and access to OMMs to ensure equitable care.
• Acknowledge scarcity of head-to-head trials and subgroup analyses limiting personalized pharmacotherapy.

Patient & Prescribing Data

Patients with obesity and obesity-related complications, including those with overweight and diverse BMI categories

OMMs induce substantial weight loss and improve multiple ORCs; however, patient adherence and access may influence treatment duration and outcomes.

Clinical Best Practices

• Adopt a person-centered approach integrating ORC assessment beyond BMI for treatment decisions.
• Use the EASO pharmacological algorithm as a living document, updating as new evidence and therapies emerge.
• Develop practical tools (decision trees, digital apps) to facilitate algorithm implementation in routine care.
• Promote lifestyle changes alongside pharmacotherapy, especially during treatment transitions.
• Collaborate internationally to refine evidence, address equity, and translate advances into patient-centered care.

References

• European Association for the Study of Obesity (EASO) Pharmacological Algorithm